Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
220 hedge funds and large institutions have $5.24B invested in Kite Pharma, Inc. in 2017 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 82 increasing their positions, 74 reducing their positions, and 27 closing their positions.
102% more call options, than puts
Call options by funds: $167M | Put options by funds: $82.6M
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
48% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 27
38% more capital invested
Capital invested by funds: $3.81B → $5.24B (+$1.43B)
11% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 74
5% more funds holding
Funds holding: 209 → 220 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$156M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$73.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$65.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$39.2M |
| 5 |
BlackRock
New York
|
+$30.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BII
Bainco International Investors
Boston,
Massachusetts
|
-$69.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.2M |
| 4 |
HCM
Highline Capital Management
New York
|
-$30.5M |
| 5 |
Jennison Associates
New York
|
-$29.5M |
KITE Hedge Fund Activity: Q2 2017 in Review
220 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q2 2017, worth a combined $5.24B — up 38% from $3.81B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new KITE positions and 27 closed out — a net gain of 13 holders — while 82 added to existing stakes and 74 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $156M. The largest seller was Bainco International Investors, cutting an estimated $69.5M.
- 220 institutional investors held Kite Pharma, Inc. (KITE) as of Q2 2017, up from 209 in Q1 2017.
- Funds reported $5.24B of Kite Pharma, Inc. stock for Q2 2017, up 38% quarter-over-quarter.
- 40 funds opened new Kite Pharma, Inc. positions in Q2 2017 and 27 closed out, a net change of +13 holders.
- The largest Kite Pharma, Inc. buyer in Q2 2017 was T. Rowe Price Associates, an estimated $156M added.
- The largest Kite Pharma, Inc. seller in Q2 2017 was Bainco International Investors, an estimated $69.5M sold.
Based on aggregated 13F filings for Q2 2017.